Mind the gap in kidney care: Translating what we know into what we do.
World Kidney Day
chronic kidney disease
equity
kidney care
public health
Journal
Journal of renal care
ISSN: 1755-6686
Titre abrégé: J Ren Care
Pays: United States
ID NLM: 101392167
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
15
04
2024
accepted:
15
04
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
ppublish
Résumé
Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-91Subventions
Organisme : None
Informations de copyright
© 2024 The Authors. Journal of Renal Care published by John Wiley & Sons Ltd on behalf of European Dialysis & Transplant Nurses Association/European Renal Care Association.
Références
Agarwal, R., Filippatos, G., Pitt, B., Anker, S.D., Rossing, P., Joseph, A. et al. (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal, 43, 474–484.
Ardavani, A., Curtis, F., Khunti, K. & Wilkinson, T.J. (2023) The effect of pharmacist‐led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta‐analysis protocol. Health Science Reports, 6(1), e1064. https://doi.org/10.1002/hsr2.1064
Bikbov, B., Purcell, C.A., Levey, A.S., Smith, M., Abdoli, A., Abebe, M. et al. (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 395, 709–733.
Chu, C.D., Chen, M.H., McCulloch, C.E., Powe, N.R., Estrella, M.M., Shlipak, M.G. et al. (2021) Patient awareness of CKD: a systematic review and meta‐analysis of patient‐oriented questions and study setting. Kidney Medicine, 3, 576–585.e1.
Chu, L., Bhogal, S.K., Lin, P., Steele, A., Fuller, M., Ciaccia, A. et al. (2022) AWAREness of diagnosis and treatment of chronic kidney disease in adults with type 2 diabetes (AWARE‐CKD in T2D). Canadian Journal of Diabetes, 46, 464–472.
Cirillo, L., Ravaglia, F., Errichiello, C., Anders, H.J., Romagnani, P. & Becherucci, F. (2022) Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatric Nephrology, 37, 2997–3008.
Dev, V., Mittal, A., Joshi, V., Meena, J.K., Dhanesh Goel, A., Didel, S. et al. (2024) Cost analysis of telemedicine use in paediatric nephrology‐the LMIC perspective. Pediatric Nephrology, 39, 193–201.
Donohue, J.F., Elborn, J.S., Lansberg, P., Javed, A., Tesfaye, S., Rugo, H. et al. (2023) Bridging the “know‐do” gaps in five non‐communicable diseases using a common framework driven by implementation science. Journal of Healthcare Leadership, 15, 103–119.
Ene‐Iordache, B., Perico, N., Bikbov, B., Carminati, S., Remuzzi, A., Perna, A. et al. (2016) Chronic kidney disease and cardiovascular risk in six regions of the world (ISN‐KDDC): a cross‐sectional study. Lancet Globalization and health, 4, e307–e319.
Essue, B.M., Laba, M., Knaul, F., Chu, A., Van Minh, H. & Nguyen, T.K.P. et al. (2017) Economic burden of chronic ill health and injuries for households in low‐ and middle‐income countries. In: Jamison, D.T., Gelband, H. & Horton, S. (Eds.) Disease control priorities: improving health and reducing poverty, 3rd edition. Washington, DC: The International Bank for Reconstruction and Development/The World Bank. Available from: https://doi.org/10.1596/978-1-4648-0527-1_ch6
Fernández‐Fernandez, B., Sarafidis, P., Soler, M.J. & Ortiz, A. (2023) EMPA‐KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clinical Kidney Journal, 16, 1187–1198.
Francis, A., Abdul Hafidz, M.I., Ekrikpo, U.E., Chen, T., Wijewickrama, E., Tannor, E.K. et al. (2022) Barriers to accessing essential medicines for kidney disease in low‐ and lower middle‐income countries. Kidney International, 102, 969–973.
Geldsetzer, P., Manne‐Goehler, J., Marcus, M.E., Ebert, C., Zhumadilov, Z., Wesseh, C.S. et al. (2019) The state of hypertension care in 44 low‐income and middle‐income countries: a cross‐sectional study of nationally representative individual‐level data from 1.1 million adults. The Lancet, 394, 652–662.
Grams, M.E., Yang, W., Rebholz, C.M., Wang, X., Porter, A.C., Inker, L.A. et al. (2017) Risks of adverse events in advanced CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. American Journal of Kidney Diseases, 70, 337–346.
Gregg, E.W., Buckley, J., Ali, M.K., Davies, J., Flood, D., Mehta, R. et al. (2023) Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. The Lancet, 401, 1302–1312.
Gummidi, B., John, O., Ghosh, A., Modi, G.K., Sehgal, M., Kalra, O.P. et al. (2020) A systematic study of the prevalence and risk factors of CKD in Uddanam, India. Kidney International Reports, 5, 2246–2255.
Heerspink, H.J.L., Vart, P., Jongs, N., Neuen, B.L., Bakris, G., Claggett, B. et al. (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25, 3327–3336.
Hole, B., Scanlon, M. & Tomson, C. (2023) Shared decision making: a personal view from two kidney doctors and a patient. Clinical Kidney Journal, 16, i12–i19.
van der Horst, D.E.M., Hofstra, N., van Uden‐Kraan, C.F., Stiggelbout, A.M., van den Dorpel, M.A., Pieterse, A.H. et al. (2023) Shared decision making in health care visits for CKD: patients' decisional role preferences and experiences. American Journal of Kidney Diseases, 82, 677–686.
Institute for Health Metrics and Evaluation (IHME). (2019). GBD compare data visualization. Available from: http://vizhub.healthdata.org/gbd-compare [Accessed 18th November 2023].
International Society of Nephrology. (2023) ISN Global Kidney Health Atlas, 3rd edition. Cranford, NJ: ISN. Available from: https://www.theisn.org/initiatives/global-kidney-health-atlas/
Ismail, W.W., Witry, M.J. & Urmie, J.M. (2023) The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. Journal of Managed Care & Specialty Pharmacy, 29, 449–463.
Jager, K.J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V. & Zoccali, C. (2019) A single number for advocacy and communication‐worldwide more than 850 million individuals have kidney diseases. Kidney International, 96, 1048–1050.
Joshi, R., John, O. & Jha, V. (2017) The potential impact of public health interventions in preventing kidney disease. Seminars in Nephrology, 37, 234–244.
Kalyesubula, R., Conroy, A.L., Calice‐Silva, V., Kumar, V., Onu, U., Batte, A. et al. (2022) Screening for kidney disease in low‐ and middle‐income countries. Seminars in Nephrology, 42, 151315.
Kamath, N. & Iyengar, A.A. (2017) Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. The Indian Journal of Pediatrics, 84, 822–825.
Ke, C., Liang, J., Liu, M., Liu, S. & Wang, C. (2022) Burden of chronic kidney disease and its risk‐attributable burden in 137 low‐and middle‐income countries, 1990‐2019: results from the global burden of disease study 2019. BMC Nephrology, 23, 17.
Khatib, R., McKee, M., Shannon, H., Chow, C., Rangarajan, S., Teo, K. et al. (2016) Availability and affordability of cardiovascular disease medicines and their effect on use in high‐income, middle‐income, and low‐income countries: an analysis of the PURE study data. The Lancet, 387, 61–69.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International, 99(3S), S1–S87.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1–S127.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105, S117–S314. Available from: https://doi.org/10.1016/j.kint.2023.10.018
Kidney Health Australia. Transforming Australia's kidney health: a call to action for early detection and treatment of chronic kidney disease. Available from: https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economic-benefits-of-early-detection-and-treatment.pdf [Accessed 16th January 2024].
Kingori, P., Peeters Grietens, K., Abimbola, S. & Ravinetto, R. (2023) Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Global Health, 6, e012902.
Kruk, M.E., Gage, A.D., Joseph, N.T., Danaei, G., García‐Saisó, S. & Salomon, J.A. (2018) Mortality due to low‐quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. The Lancet, 392, 2203–2212.
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.A., Fogo, A.B. et al. (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 390, 1888–1917.
Luyckx, V.A., Tonelli, M. & Stanifer, J.W. (2018) The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization, 96, 414–422D.
McEwan, P., Boyce, R., Sanchez, J.J.G., Sjöström, C.D., Stefansson, B., Nolan, S. et al. (2023) Extrapolated longer‐term effects of the DAPA‐CKD trial: a modelling analysis. Nephrology Dialysis Transplantation, 38, 1260–1270.
Mishra, S.R., Neupane, D., Preen, D., Kallestrup, P. & Perry, H.B. (2015) Mitigation of non‐communicable diseases in developing countries with community health workers. Globalization and Health, 11, 43.
Musacchio, N., Zilich, R., Ponzani, P., Guaita, G., Giorda, C., Heidbreder, R. et al. (2023) Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. Journal of Diabetes, 15, 224–236.
Neumiller, J.J., Alicic, R.Z. & Tuttle, K.R. (2021) Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Advances in Chronic Kidney Disease, 28, 318–327.
Nguyen‐Thi, H.Y., Le‐Phuoc, T.N., Tri Phat, N., Truong Van, D., Le‐Thi, T.T., Le, N. et al. (2021) The economic burden of chronic kidney disease in Vietnam. Health Services Insights, 14, 117863292110360.
Nicholas, S.B., Daratha, K.B., Alicic, R.Z., Jones, C.R., Kornowske, L.M., Neumiller, J.J. et al. (2023) Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019–2020. Diabetes, Obesity and Metabolism, 25, 2970–2979.
Nuffield Department of Population Health Renal Studies Group. (2022) SGLT2 Inhibitor Meta‐Analysis Cardio‐Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co‐transporter‐2 inhibitors on kidney outcomes: collaborative meta‐analysis of large placebo‐controlled trials. Lancet, 400, 1788–1801.
Pan American Health Organization. (2023) Quality control of medicines. Available from: https://www.paho.org/en/topics/quality-control-medicines [Accessed 18th November 2023].
Patel, A., Praveen, D., Maharani, A., Oceandy, D., Pilard, Q., Kohli, M. et al. (2019) Association of multifaceted mobile technology‐enabled primary care intervention with cardiovascular disease risk management in rural Indonesia. JAMA Cardiology, 4, 978–986.
Peralta, C.A., Livaudais‐Toman, J., Stebbins, M., Lo, L., Robinson, A., Pathak, S. et al. (2020) Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. American Journal of Kidney Diseases, 76, 636–644.
Population Health Research Institute. (2023). Polypills added to WHO essential medicines list. Available from: https://www.phri.ca/eml/ [Accessed 18th November 2023].
Porter, J., Boyd, C., Skandari, M.R. & Laiteerapong, N. (2023) Revisiting the time needed to provide adult primary care. Journal of General Internal Medicine, 38, 147–155.
Ramakrishnan, C., Tan, N.C., Yoon, S., Hwang, S.J., Foo, M., Paulpandi, M. et al. (2022) Healthcare professionals' perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Services Research, 22, 560.
Rangaswami, J., Tuttle, K. & Vaduganathan, M. (2020) Cardio‐renal‐metabolic care models: toward achieving effective interdisciplinary care. Circulation: Cardiovascular Quality and Outcomes, 13(11). https://doi.org/10.1161/CIRCOUTCOMES.120.007264
Rios, P., Sola, L., Ferreiro, A., Silvariño, R., Lamadrid, V., Ceretta, L. et al. (2022) Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One, 17, e0266617.
Rubin, R. (2023) It takes an average of 17 years for evidence to change practice—the burgeoning field of implementation science seeks to speed things up. Journal of the American Medical Association, 329, 1333–1336.
Sepanlou, S.G., Mann, J.F.E., Joseph, P., Pais, P., Gao, P., Sharafkhah, M. et al. (2023) Fixed‐dose combination therapy for the prevention of cardiovascular diseases in CKD: an individual participant data meta‐analysis. Clinical Journal of the American Society of Nephrology, 18, 1408–1415.
Sherrod, C.F., Farr, S.L. & Sauer, A.J. (2023) Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion? European Heart Journal, 44, 1970–1972.
Stengel, B., Muenz, D., Tu, C., Speyer, E., Alencar de Pinho, N., Combe, C. et al. (2021) Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney International Reports, 6, 437–448.
Stevenson, J.K., Campbell, Z.C. & Webster, A.C. et al. (2019) eHealth interventions for people with chronic kidney disease. Cochrane Database of Systematic Reviews, 8, CD012379.
Taha, A., Iman, Y., Hingwala, J., Askin, N., Mysore, P., Rigatto, C. et al. (2022) Patient navigators for CKD and kidney failure: a systematic review. Kidney Medicine, 4, 100540.
Tuot, D.S., Crowley, S.T., Katz, L.A., Leung, J., Alcantara‐Cadillo, D.K., Ruser, C. et al. (2022) Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think‐aloud study. JMIR Formative Research, 6, e40001.
Tuttle, K.R., Alicic, R.Z., Duru, O.K., Jones, C.R., Daratha, K.B., Nicholas, S.B. et al. (2019) Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE‐CKD registry. JAMA Network Open, 2, e1918169.
Tuttle, K.R., Bosch‐Traberg, H., Cherney, D.Z.I., Hadjadj, S., Lawson, J., Mosenzon, O. et al. (2023) Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney International, 103, 772–781.
Tuttle, K.R., Wong, L., St Peter, W., Roberts, G., Rangaswami, J., Mottl, A. et al. (2022) Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clinical Journal of the American Society of Nephrology, 17, 1092–1103.
US Renal Data System. (2023) Healthcare expenditures for persons with CKD. Accessed November 18, 2023 Available from: https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd
Vanholder, R., Annemans, L., Braks, M., Brown, E.A., Pais, P., Purnell, T.S. et al. (2023) Inequities in kidney health and kidney care. Nature Reviews Nephrology, 19, 694–708.
Vanholder, R., Annemans, L., Brown, E., Gansevoort, R., Gout‐Zwart, J.J., Lameire, N. et al. (2017) Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nature Reviews Nephrology, 13, 393–409.
Verberne, W.R., Stiggelbout, A.M., Bos, W.J.W. & van Delden, J. (2022) Asking the right questions: towards a person‐centered conception of shared decsision‐making regarding treatment of advanced chronic kidney disease in older patients. BMC Medical Ethics, 23, 47.
World Health Organization. (2013–2023). Mid‐point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020 (NCD‐GAP). Available from: https://cdn.who.int/media/docs/default-source/documents/about-us/evaluation/ncd-gap-final-report.pdf?sfvrsn=55b22b89_5&download=true [Accessed 18th November 2023].
Zuniga, C., Riquelme, C., Muller, H., Vergara, G., Astorga, C. & Espinoza, M. (2020) Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney International Reports, 5, 920–923.